Abstract: The invention relates to new substituted imidazotriazines, processes for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative disorders, in particular of Parkinson's disease and of schizophrenia.

Abstract: The invention provides a human GPR40 which is associated with the hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, respiratory diseases, metabolic disease, cancer, cardiovascular diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, respiratory diseases, metabolic disease, cancer, cardiovascular diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR40 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human GPR14 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, urological diseases, endocrinological diseases and cancer. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, urological diseases, endocrinological diseases and cancer. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR14 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human HM74a which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, cancer, inflammation, urological diseases, respiratory diseases and gastroen-terological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, cancer, inflammation, uro-logical diseases, respiratory diseases and gastroenterological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of HM74a as well as pharmaceutical compositions comprising such compounds.

Abstract: Reagents which regulate human prostasin-like enzyme activity and reagents which bind to human prostasin-like enzyme gene products can be used to regulate human prostasin-like enzyme activity. Such regulation is particularly useful for treating metastasis of malignant cells, tumor angiogenesis, inflammation, atherosclerosis, neurodegenerative diseases, and pathogenic infections.

Abstract: The invention relates to the use of compounds that stimulate cGMP, in particular imidazo[1,3,5]triazinones, for producing a medicament for the treatment and/or prophylaxis of diseases, in which the clinical picture can be improved and/or cured by the improvement of the micro-circulation of tissue containing a phosphodiesterase that metabolises cGMP.

Abstract: The present invention relates to carboxamides which are useful as an active ingredient of pharmaceutical preparations. The carboxamides of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity.

Abstract: This invention relates to tetrahydro-naphthalene derivatives of formula (I) in which the variable groups are as defined in the specification and claims, and tautomeric and stereoisomeric forms and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD. The compounds, pharmaceutical compositions containing them, and methods of treatment using them are disclosed and claimed.

Abstract: The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory diseases

Abstract: In a process for the quantitative optical analysis of fluorescently labelled biological cells 5, a cell layer on a transparent support at the bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing the fluorescent dye 4. The sensitivity of analytical detection can be considerably improved if to the fluorescent dye 4 already present in addition a masking dye 9, which absorbs the excitation light 6 for the fluorescent dye 4 and/or its emission light 7, is added to the solution 3 and/or if a separating layer 10 permeable to the solution and absorbing and/or reflecting the excitation light 6 or the emission light 7 is applied to the cell layer at the bottom 2. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. The separating layer 10 must in this case be composed such that it has a high power of reflection for the luminescent light 11.

Abstract: This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. They have the general formula (I) in which R1 represents hydrogen or C1-6 alkyl, and X represents —N(H)Y1, —N(H)—C1-6 alkylene Y1, biphenyl or C1-6 alkyl substituted by biphenyl, and the group Y1 is an optionally substituted biphenyl. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

Abstract: Reagents which regulate human protein phosphatase IIC-like enzyme-like enzyme activity and reagents which bind to human protein phosphatase IIC-like enzyme-like enzyme gene products can be used, inter alia, to treat disorders associated with an increase in apoptosis, including AIDS and other infectious or genetic immunodeficiencies, neurodegenerative diseases, myelodysplasia, ischemic injuries, toxin-induced diseases, wasting diseases, viral infections, and osteoporosis. Regulation of human protein phosphatase IIC-like enzyme-like enzyme also can be used to treat disorders associated with a decrease in apoptosis, including cancer, diabetes, CNS disorders, cardiovascular disorders, chronic obstructive pulmonary diseases, and inflammatory disorders also can be treated.

Abstract: Reagents that regulate human WEE1-like serine/threonine protein kinase and reagents which bind to human WEE1-like serine/threonine protein kinase gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, cancer, peripheral and central nervous system disorders, genitourinary disorders, cardiovascular disorders, and COPD.

Abstract: The invention provides a human PDE10A which is associated with the disorders of the peripheral and central nervous system (e.g. Alzheimer), cardiovascular diseases, cancer (e.g. thyroid, oesophagus, stomach, liver, ovary, kidney), gastroenterological diseases (e.g. liver cirrhosis), endocrinological diseases and urological diseases (e.g. benign prostate hyperplasia). The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, cancer, gastroenterological diseases, endocrinological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE10A as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention relates to novel alkyl-substituted pyrazolopyrimidines, process for their preparation, and the use thereof for producing medicaments for improving perception, concentration, learning and/or memory.

Abstract: Reagents that regulate human MRP5-like protein and reagents which bind to human MRP5-like protein gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, cardiovascular disorders, cancer, and CNS disorders.

Abstract: Reagents which regulate human prostasin-like enzyme activity and reagents which bind to human prostasin-like enzyme gene products can be used to regulate human prostasin-like enzyme activity. Such regulation is particularly useful for treating metastasis of malignant cells, tumor angiogenesis, inflammation, atherosclerosis, neurodegenerative diseases, and pathogenic infections.

Abstract: Reagents that regulate human serine-threonine protein kinase and reagents which bind to human serine-threonine protein kinase gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, cancer, diabetes, COPD, and peripheral and central nervous system disorders.

Abstract: The invention relates to compounds of formula (I), to a method for the production thereof, and to the use of the same as pharmaceuticals for the treatment of diseases in humans and/or animals

Abstract: The invention relates to novel dihydropyridinone derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.